Advertisement

The concentration of u-PA and PAI-1 antigen in tissue extracts of nasopharyngeal carcinoma

  • M. Sunagawa
  • G. W. Huang
  • M. Nakamura
  • T. Kosugi
Original Paper

Abstract

We measured the antigen levels of urokinasetype plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in tissue extracts from nasopharyngeal carcinomas. An increase in u-PA antigen was observed with the advanced stages of disease. However, the levels of PAI-1 antigen decreased with each advanced stage. These results suggest that local administration of antiplasminic agents may be effective in suppressing tumor invasion.

Key words

Nasopharyngeal carcinoma Urokinasetype plasminogen activator Plasminogen activator inhibitor-1 Tumor invasion 

References

  1. 1.
    Carrell RW, Boswell DR (1986) Serpins: the superfamily of plasma proteinase inhibitors. In: Barrett A, Salvesen S, (eds) Proteinase inhibitors. Elsevier, Amsterdam, pp 403–420Google Scholar
  2. 2.
    Danø K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators tissue degradation, and cancer. Adv Cancer Res 44: 139–266PubMedCrossRefGoogle Scholar
  3. 3.
    Kosugi T, Huang G-W, Nakamura M, Koja S, Nong H-T (1990) Identification of a plasminogen activator derived from nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 247: 374–378PubMedGoogle Scholar
  4. 4.
    Lowry OH, Rosenbrough NJ, Farr AL, Randall JR (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–295PubMedGoogle Scholar
  5. 5.
    Markus G, Camiolo SM, Kohga S, Madeja JM, Mittelman A (1983) Plasminogen activator secretion of human tumor in short-term organ culture, including a comparison of primary and metastatic colon tumors. Cancer Res 43: 5517–5525PubMedGoogle Scholar
  6. 6.
    Nagayama M, Sato A, Hayakawa H, Urano T, Takada Y, Takada A (1994) Plasminogen activators and their inhibitors nonsmall cell lung cancer: low content of type 2 palsminogen activator inhibitors associated with tumor dissemination. Cancer 73: 1398–1405PubMedCrossRefGoogle Scholar
  7. 7.
    Nishino N, Aoki K, Tokura Y, Sakaguchi S, Takada Y, Takada A (1988) The urokinase type of plasminogen activator in cancer of digestive tract. Thromb Res 50: 527–535PubMedCrossRefGoogle Scholar
  8. 8.
    Pappot H, Gårdsvoll H, Rømer J, Pedersen AN, Grøndahl-Hansen J, Pyke J, Brünner N (1995) Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol Chem Hoppe-Seyler 376: 259–267PubMedGoogle Scholar
  9. 9.
    Saksela O, Rifkin DB (1988) Cell-associated plasminogen activator: regulation and physiological function. Annu Rev Cell Biol 4: 93–126PubMedCrossRefGoogle Scholar
  10. 10.
    Schwab W, Clasen B, Steinhoff H-J (1987) Neue und geänderte Richtlinien zum TNM-System im Kopf-Hals-Bereich. HNO 35: 112–118PubMedGoogle Scholar
  11. 11.
    Sumiyoshi K, Baba S, Sakaguchi S, Urano T, Takada Y, Takada A (1991) Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis. Thromb Res 63: 59–71PubMedCrossRefGoogle Scholar
  12. 12.
    Vassalli J-D, Sapppino A-P, Belin D (1991) The plasminogen activator/plasmin system. J Clin Invest 88: 1067–1072PubMedCrossRefGoogle Scholar
  13. 13.
    Wiman B, Almquist Å, Sigurdardottir O, Lindahl T (1988) Plasminogen activator inhibitor 1 (PAI-1) is bound to vitronectin in plasma. FEBS Lett 242: 125–128PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • M. Sunagawa
    • 1
  • G. W. Huang
    • 3
  • M. Nakamura
    • 1
  • T. Kosugi
    • 2
  1. 1.1st Department of Physiology, School of MedicineUniversity of the RyukyusOkinawaJapan
  2. 2.1st Department of Physiology and The Research Center of Comprehensive Medicine, School of MedicineUniversity of the RyukyusOkinawaJapan
  3. 3.Department of OtorhinolaryngologyGuangxi Medical UniversityGuangxi P.R.China

Personalised recommendations